Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

TxCell Enters Col-Treg into Full Development for the Rare Disease Autoimmune Uveitis

Published: Wednesday, January 08, 2014
Last Updated: Wednesday, January 08, 2014
Bookmark and Share
Col-Treg is second product candidate from TxCell’s proprietary personalized cellular immunotherapy platform – ASTrIA.

TxCell SA has announced that it has initiated a full development program with Col-Treg for the treatment of Autoimmune Uveitis. Col-Treg is TxCell’s second therapeutic candidate from its ASTrIA platform after Ovasave®, TxCell’s lead autologous Ag-Treg cell-based immunotherapy.

Autoimmune Uveitis is a serious inflammatory condition of the eye that often results in permanent vision damage. Uveitis is classified as a rare disease with a prevalence of around 35-50/100,000, with Autoimmune Uveitis constituting 80-90% of cases.

Despite its rarity, in developed countries this autoimmune disease causes 10-15% of legal blindness. The condition also leads to 30,000 new cases of blindness per year in the US alone and affects around 168,000 people in Europe.

“Though Autoimmune Uveitis is a rare disease, it is a leading cause of blindness and can take a terrible toll. Unfortunately, Autoimmune Uveitis also has very limited treatment options, and new ones are urgently needed,” said Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs of TxCell.

The current first-line treatment consists of corticosteroids, often used with antimetabolites and alkylating agents. However, there are currently no approved options for the 50% of patients that become refractory to steroid compounds. The development of Col-Treg for treatment of steroid refractory patients could bring a new therapeutic possibility for these patients.

“The launch of Col-Treg, TxCell’s second full development program, will allow TxCell to potentially create a novel, personalized cellular immunotherapy approach to reduce the terrible burden of uveitis,” said Damian Marron, Chief Executive Officer of TxCell. “The development of the approach is made possible by the breadth of TxCell’s ASTrIA technology platform. This technology is central to TxCell's strategy of targeting orphan/niche indications with poor or no treatment options.”

In recent years, a number of scientific studies have examined several experimental models of Autoimmune Uveitis. Those studies have demonstrated that the administration or induction of regulatory T (Treg) cells in vivo can be used as therapeutic tools for the control of ocular inflammation. As a result, TxCell has developed Col-Treg as a proprietary personalized cellular immunotherapy.

Col-Treg is based on the regulatory properties of autologous collagen-II specific regulatory T lymphocytes. It is specifically designed to exert its suppressive and anti-inflammatory action upon recognition of collagen-II, a protein present in the vitreous body of the eye. TxCell has already shown efficacy for Col-Treg in models of autoimmune diseases and has also shown absence of toxicity in a 6-month toxicology study performed under Good Laboratory Practices (GLP).

The first stage of the new Col-Treg program will be to complete the required pre-requisites for applying orphan drug designations in the European Union and in the United States and to prepare for a phase II proof of principle study to start in 2015.

In addition, TxCell will request Advanced Therapy Medicinal Product (ATMP) classification by the European Medicines Agency (EMA) for this new personalized cell-based product.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell to Present its Cellular Immunotherapy Developments
Dr. Miguel Forte and Dr. Arnaud Foussat will present at three forthcoming leading cell and gene therapy and ophthalmology conferences.
Friday, September 18, 2015
TxCell Granted US Orphan Drug Designation for Col-Treg
A first-in-man clinical study is planned to start in 2016, with top line results expected end 2017.
Tuesday, September 15, 2015
TxCell Announces Publication of Preclinical Efficacy Results for Col-Treg
Results published in Investigative Ophthalmology and Visual Science (IOVS) provide details on the demonstration of Col-Treg’s therapeutic potential in autoimmune uveitis and will support its ongoing clinical development.
Thursday, September 10, 2015
TxCell Receives Fast Track Designation from FDA for Ovasave®
TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease.
Wednesday, August 05, 2015
TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®
First clinical batches could be manufactured as soon as Q2 2016.
Saturday, August 01, 2015
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Strengthening of Cash Position and Development of ASTrIA Product Platform
Positive results for Col-Treg, second product candidate, in an auto-immune uveitis model.
Tuesday, April 07, 2015
TxCell to Present at Upcoming US and French Investment Conferences
Conferences include Alliance for Regenerative Medicine's 3rd Annual Regen Med Investor Day, New York, March 25 and the Portzamparc PEA-PME Forum, Paris, April 1.
Saturday, March 28, 2015
Key TxCell Patent to be Granted in the US for its Lead Product Ovasave®
Patent ensures protection for Ovasave® in the US until 2030 minimum.
Thursday, March 19, 2015
TxCell to Present at ROTH Capital Partners Investor Conference in US
TxCell invited to speak at largest US meeting for investors in emerging growth companies.
Friday, February 27, 2015
TxCell Reports Revenues for 2014 and Updates on Upcoming Milestones
Ovasave and Col-Treg regulatory status update in the United States, expected mid-2015.
Thursday, February 05, 2015
Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Michigan Researchers Use Raman Spectroscopy
inVia confocal Raman microscope used in the study of various childhood diseases.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos